Daxor (NASDAQ:DXR) Stock Price Up 13.5% – Here’s Why

Daxor Corporation (NASDAQ:DXR) shares traded up 13.5% during mid-day trading on Tuesday . The company traded as high as $13.51 and last traded at $13.00. 21,337 shares traded hands during trading, an increase of 249% from the average session volume of 6,105 shares. The stock had previously closed at $11.45.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “hold (c-)” rating on shares of Daxor in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Daxor presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.00.

Daxor Price Performance

The company’s 50-day simple moving average is $12.14 and its 200-day simple moving average is $10.00.

Institutional Trading of Daxor

An institutional investor recently bought a new position in Daxor stock. Osaic Holdings Inc. acquired a new stake in Daxor Corporation (NASDAQ:DXR) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 8,750 shares of the company’s stock, valued at approximately $86,000. Osaic Holdings Inc. owned approximately 0.18% of Daxor as of its most recent SEC filing. Hedge funds and other institutional investors own 1.34% of the company’s stock.

Daxor Company Profile

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.